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Conclusion: After carotid endarterectomy (CEA) or carotid artery
stenting (CAS), restenosis and occlusion of the internal carotid artery are
infrequent and occur at the same rate for the two procedures.
Summary: In the CREST trial, the frequency of the composite end
point of myocardial infarction, stroke, or death during the periprocedural
period, or ipsilateral stroke thereafter, occurred equally with CEA and
CAS. A secondary analysis indicated that stroke was more frequent after
CAS and myocardial infarction, primarily enzyme leaks, was more frequent
after CEA. A secondary predescribed goal of CREST was to determine the
composite end point of restenosis or occlusion after the two procedures.
The original prespeciﬁed times for analysis were 6 and 12 months. However,
the investigators agreed that analysis at 24 months would be more informa-
tive, and thus, this article reports 2-year anatomic durability of CAS and
CEA. This was a per protocol analysis. CREST enrolled patients with
stenosis of the internal carotid artery who were asymptomatic or who had
a transient ischemic attack, amaurosis fugax, or a minor stroke. The study
involved 117 centers in the United States and Canada, and enrollment
occurred between December 21, 2000, and January 18, 2008. Restenosis
and occlusion were assessed by duplex ultrasound imaging at 1, 6, 12, 24,
and 48 months. Restenosis was deﬁned as a reduction in diameter of the
target artery of at least 70%. A peak systolic velocity of 300 cm/s was
used as an indicator of 70% stenosis. All studies were done in CREST-certi-
ﬁed laboratories and were interpreted at an ultrasound core laboratory at the
University of Washington. Frequency of restenosis was calculated by
Kaplan-Meier survival estimates and was compared at 2 years. Proportional
hazard models were used to estimate the association between baseline char-
acteristics and risk of restenosis. In the CREST study, 2191 patients
received their assigned treatment #30 days of randomization and had
eligible ultrasound images (1086 who had CAS, 1,105 who had CEA).
In 2 years, 58 patients treated with CAS (Kaplan-Meier rate, 6.0%) and
62 patients who had CEA (6.3%) had restenosis or occlusion (hazard ratio,
0.9; 95% conﬁdence interval, 0.63-1.29; P ¼ .58). Independent predictors
of restenosis or occlusion after both procedures (hazard ratio, 95% conﬁ-
dence interval) were female sex (1.79, 1.25-2.56), dyslipidemia (2.07,
1.01-4.26), and diabetes (2.31, 1.61-3.31). Smoking was a risk factor for
an increased rate of restenosis after CEA (2.26, 1.34-3.77) but not after
CAS (0.77, 0.41-1.42). Deﬁning restenosis as a peak systolic velocity of
230, 350, or 400 cm/s did not result in a difference in the frequency of
restenosis between CAS and CEA. Using a restenosis deﬁnition of 210
cm/s indicated increased restenosis after CAS (14.8%) vs CEA (10.5%).
Participants who had restenosis or occlusion at 2 years with adjustment
for age, sex, and symptomatic status had an increased risk for ipsilateral
stroke during the follow-up period (hazard ratio, 4.37, 95% conﬁdence
interval, 9.91-10.03; P ¼ .0005).
Comment: The article indicates that CAS and CEA both provide
anatomically durable results out to 2 years after treatment. Concerns
expressed by many of increased restenosis after CAS are not supported by
the CREST data, at least at 2 years. It is important to note that the authors’
data also suggest an increased risk of stroke after restenosis with either
procedure. However, there were very few reinterventions for restenosis in
the CREST patients, and the data cannot be used to determine whethertreatment of restenosis following either CAS or CEA will decrease overall
stroke risk.The Effect of Medical Treatments on Stroke Risk in Asymptomatic
Carotid Stenosis
King A, Shipley M, Markus H, et al., and the ACES Investigators. Stroke
2013;44:542-6.
Conclusion: In patients with asymptomatic carotid stenosis (ACS),
blood pressure control and antiplatelet therapy are the most important
factors to reduce short-term stroke and cardiovascular risk.
Summary: There is evidence that with modern medical therapy,
stroke risk in patients currently asymptomatic with signiﬁcant carotid
stenosis is less than that present during the time of the two large trials
of carotid endarterectomy (CEA) for ACS (Spence JD et al, Nat Rev Neu-
rol 2010;6:477-86). In addition, prospective population-based studies have
also suggested a lower current risk of ipsilateral stroke in patients with ACS
(Marquardt L et al, Stroke 2010;41:e11-7). The authors point out that if
medical management is to be used in the management of ACS, it is useful
to determine which elements of medical management provide the greatest
beneﬁt. Using data from the Asymptomatic Carotid Emboli Study
(ACES), the authors sought to determine how changes in current medica-
tions inﬂuence the risk of ACS. ACES was an international multicenter
study of patients with ACS who were monitored for 2 years. Stroke or
transient ischemic attack (TIA) and blood pressures were recorded every
6 months. In addition, treatment changes were evaluated every 6 months
to allow comparison of the effects of baseline treatments with current treat-
ment in conjunction with risk factors over the 6-month interval on the risk
of stroke, TIA, and cardiovascular disease. There were 477 patients with
ACS followed up every 6 months for 2 years. Time-dependent Cox regres-
sion analysis was used to determine the relationship between current treat-
ment over time and risk of stroke, TIA, and cardiovascular death as end
points. Antiplatelet agents (P ¼ .001) and lower mean blood pressure (P
¼ .002) were independent predictors of reduced risk of ipsilateral stroke
and TIA in patients with ACS. Antiplatelet agents (P < .0001) and antihy-
pertensive drugs (P < .0001) were independent predictors of a lower risk
of any stroke or cardiovascular death. On univariate analysis, statin medica-
tions were associated with a lower risk of ipsilateral stroke or TIA (P ¼ .04)
and of any stroke or cardiovascular death (P < .0001). However, multivari-
able analysis indicated statins were not predictors of ipsilateral stroke or
TIA nor were statins or age predictors of any stroke or cardiovascular
death.
Comment: In addition to control of risk factors, the data indicate that
the most important elements of medical management of ACS are the use of
antiplatelet agents and blood pressure control. The authors postulate that
the lack of effect of statin medications in this study may reﬂect a relatively
short duration of follow-up. However, in the Stroke Prevention by Aggres-
sive Reduction in Cholesterol Levels (SPARCL) Trial, risk reduction began
to appear after 1 to 2 years of follow-up (Goldstein LB et al, Stroke
2009;40:3526-31). Statin medications were not the focus of evaluation in
ACES, whereas in SPARCL, aggressive use of statin medications was the
focus of the trial. Therefore, the data here do not exclude statin medications
as beneﬁcial in prevention of stroke in patients with ACS. The suggestion is
there may be a dose-dependent effect of statin medication on the reduction
of stroke in patients with ACS.
